<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>47(7)</volume><submitter>Cappa M</submitter><funding>Pfizer Italia</funding><pubmed_abstract>&lt;h4>Purpose&lt;/h4>Growth hormone deficiency (GHD) is a rare condition with a worldwide prevalence of 1 patient in 4000 to 10,000 live births, placing a significant economic burden on healthcare systems. The aim of this study is to generate evidence on the economic burden of children and adolescents with GHD treated with rhGH and their parents in Italy.&lt;h4>Methods&lt;/h4>A cost of illness analysis, adopting the prevalence approach, has been developed, producing evidence on the total annual cost sustained by the Italian National Health System (NHS) and by the society. The study is based on original data collected from a survey conducted among Italian children and adolescents with GHD and their parents.&lt;h4>Results&lt;/h4>143 children/adolescents with GHD and their parents participated to the survey, </pubmed_abstract><journal>Journal of endocrinological investigation</journal><pagination>1743-1750</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11196344</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>The economic burden of pediatric growth hormone deficiency in Italy: a cost of illness study.</pubmed_title><pmcid>PMC11196344</pmcid><pubmed_authors>La Torre D</pubmed_authors><pubmed_authors>Pozzobon G</pubmed_authors><pubmed_authors>Maghnie M</pubmed_authors><pubmed_authors>Cappa M</pubmed_authors><pubmed_authors>Spandonaro F</pubmed_authors><pubmed_authors>Polistena B</pubmed_authors><pubmed_authors>Orso M</pubmed_authors><pubmed_authors>Granato S</pubmed_authors><pubmed_authors>Novelli G</pubmed_authors><pubmed_authors>Patti G</pubmed_authors><pubmed_authors>Salerno M</pubmed_authors></additional><is_claimable>false</is_claimable><name>The economic burden of pediatric growth hormone deficiency in Italy: a cost of illness study.</name><description>&lt;h4>Purpose&lt;/h4>Growth hormone deficiency (GHD) is a rare condition with a worldwide prevalence of 1 patient in 4000 to 10,000 live births, placing a significant economic burden on healthcare systems. The aim of this study is to generate evidence on the economic burden of children and adolescents with GHD treated with rhGH and their parents in Italy.&lt;h4>Methods&lt;/h4>A cost of illness analysis, adopting the prevalence approach, has been developed, producing evidence on the total annual cost sustained by the Italian National Health System (NHS) and by the society. The study is based on original data collected from a survey conducted among Italian children and adolescents with GHD and their parents.&lt;h4>Results&lt;/h4>143 children/adolescents with GHD and their parents participated to the survey, </description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Jul</publication><modification>2025-04-19T15:42:05.211Z</modification><creation>2025-04-19T15:42:05.211Z</creation></dates><accession>S-EPMC11196344</accession><cross_references><pubmed>38198073</pubmed><doi>10.1007/s40618-023-02277-z</doi></cross_references></HashMap>